Real-World Persistence and Treatment Interval in Patients with Diabetic Macular Edema Treated with Anti-Vascular Endothelial Growth Factors in the USA
Authors:
Open Access
- 22 June 2023
- journal article
- research article
- Published by Springer Nature in Ophthalmology and Therapy
- Vol. 12 (5) , 2465-2477
Abstract
Introduction There is little understanding of long-term treatment persistence in patients receiving anti-vascular endothelial growth factor (anti-VEGF) injections for diabetic macular edema (DME), particularly relating to treatment intervals. The aim of this study was to investigate the association between treatment interval and discontinuation rate after 24 months of unilateral anti-VEGF treatment in patients with DME under routine clinical care in the USA. Methods This was a non-interventional, retrospective cohort study to review the health insurance claims of adults with DME linked with the IBM MarketScan® Commercial and Medicare Supplemental databases, who were continuously enrolled in a health plan for at least 6 months prior to their first anti-VEGF treatment and for a duration of at least 24 months between July 2011 and June 2017. Patients were grouped on the basis of the injection interval they achieved at 24 months of treatment. Discontinuation rate beyond 24 months and its association with treatment intervals at 24 months was estimated using the Kaplan–Meier method and Cox proportional hazards models. Results The overall discontinuation rate among the 1702 eligible patients from 24 to 60 months after treatment initiation was 30%. At 60 months, patients were more likely to remain on treatment in shorter (75.3% [4-week interval group]) versus longer treatment interval groups (62.1% [> 12-week interval group], difference = 13.2%, [95% confidence interval (CI) 1.06, 2.06], p = 0.01). Patients on a > 12-week interval were twice as likely to discontinue treatment compared with those on an 8-week interval (hazard ratio = 2.01 [95% CI 1.43, 2.82], p < 0.001). Conclusion Patients with DME on longer anti-VEGF treatment intervals at 24 months consistently had higher discontinuation rates in the following years than those on shorter treatment intervals.Keywords
Funding Information
- Novartis Pharma AG
This publication has 26 references indexed in Scilit:
- Vascular endothelial growth factor and diabetic macular edemaSurvey of Ophthalmology, 2016
- Epidemiology of diabetic retinopathy, diabetic macular edema and related vision lossEye and Vision, 2015
- Comorbidity and Health Care Resource Use Among Commercially Insured Non-Elderly Patients With Diabetic Macular EdemaOphthalmic Surgery, Lasers and Imaging Retina, 2015
- EVOLUTION OF CONTROLLING DIABETIC RETINOPATHYRetina, 2015
- Prevalence of and Risk Factors for Diabetic Macular Edema in the United StatesJAMA Ophthalmology, 2014
- Prevalence, Demographics, and Treatment Characteristics of Visual Impairment due to Diabetic Macular Edema in a Representative Canadian CohortJournal of Ophthalmology, 2012
- Anti–Vascular Endothelial Growth Factor Pharmacotherapy for Diabetic Macular EdemaOphthalmology, 2012
- Clinical development of new treatments for diabetic macular oedemaClinical and Experimental Optometry, 2012
- Bias in Observational Studies of Prevalent Users: Lessons for Comparative Effectiveness Research From a Meta-Analysis of StatinsAmerican Journal of Epidemiology, 2012
- Burden of illness of diabetic macular edema: literature reviewCurrent Medical Research and Opinion, 2010